Cornerstone Therapeutics Announces New Analysis Shows Lower Mortality Rates and Less Need for Redosing When Treating Neonatal Respiratory Distress Syndrome With CUROSURF vs. Survanta

Cornerstone Therapeutics

announced a new analysis published in the eFirst Pages section of the Pediatrics website reporting significant benefits in mortality rate and the need for redosing when treating neonatal respiratory distress syndrome with Cornerstone's CUROSURF® (poractant alfa) Intratracheal Suspension(1). The objective of the independently performed meta-analysis was to compare the efficacy of CUROSURF versus Survanta® (beractant) and Infasurf® (calfactant) with respect to clinical outcomes among preterm infants with RDS. The analysis was led by Neetu Singh, M.D., at Dartmouth Hitchcock Medical Center.